Tag: 22nd Century Group

  • James Mish Appointed to 22nd Century Board

    James Mish Appointed to 22nd Century Board

    Photo: Bill Gallery

    22nd Century Group has appointed James A. Mish to its board of directors.

    “The board of directors is very pleased to appoint Jim to the board, recognizing his exceptional leadership in developing and executing the business strategy leading to the commercial launches of our modified-risk tobacco products as well as our hemp/cannabis lines,” said Nora B. Sullivan, chairperson of the board of directors, in a statement.

    “Bringing him onto the board further enhances our direct scientific, manufacturing and operational experience in these critically important end markets during a transformative time for our company. His contributions in the board room will also enhance the ongoing development of our strategies and ensure alignment and support for the execution of the strategic initiatives of the company.”

    Mish has served as 22nd Century Group’s CEO since June 2020. Trained as a chemist, he brings a detailed understanding of molecular, organic and formulation sciences to the board—particularly in botanical products and consumer product innovation. He also brings deep experience navigating the regulatory matters related to product approvals and clinical trials, particularly with the U.S. Food and Drug Administration, European Medicines Agency and European Food Safety Authority.

    Prior to joining 22nd Century, Mish led the private equity carve out of Noramco from Johnson & Johnson/Janssen Pharmaceuticals and the subsequent spinoff of Purisys from Noramco. Mish served as president and CEO of Purisys, leading its pharmaceutically derived cannabinoid API, ingredients and solutions business, including full-scale commercial production of cannabinoid APIs for various market segments, including pharmaceuticals, medical OTC and consumer packaged goods.

    Mish began his career at the multinational pharmaceutical firm Pfizer in research and development before holding positions of increasing responsibility at several companies.

  • 22nd Century to Launch VLN Cigarettes in U.S.

    22nd Century to Launch VLN Cigarettes in U.S.

    Photo: 22nd Century

    22nd Century Group plans to launch its VLN reduced-nicotine cigarettes in a major U.S. metropolitan market by March 2022. The debut will be followed by a nationwide launch.

    On Dec. 23, 2021, the U.S. Food and Drug Administration authorized 22nd Century Group’s VLN King and VLN Menthol King as the first reduced-nicotine content cigarettes under the agency’s modified-risk tobacco product designation. Scientific studies show the company’s VLN reduced-nicotine content cigarettes “help you smoke less.”  

    “The FDA’s MRTP authorization of VLN ushered in a new reality—a combustible cigarette carrying an authorized harm reduction claim supported by extensive scientific and clinical studies, most of which were funded by federal health agencies,” said James A. Mish, CEO of 22nd Century, in a statement.

    “VLN is the only reduced harm product of its kind, and we are confident based on the research that it can absolutely be successful on its own or in combination with other harm reduction products. With an estimated 1,300 deaths per day associated with U.S. smoking, our products that can help people smoke less offer a truly game-changing prospect for millions of American adults who currently smoke.”  

    During the pilot phase, 22nd Century Group will test and optimize its marketing mix. The pilot will help the company better understand how adult smokers will use this product prior to advancing to national distribution, providing an unmatched tool for helping adult smokers find an off-ramp from nicotine addiction.

    “22nd Century has secured a well-known national retail partner for VLN’s pilot market launch phase,” said Mish. “We intend to deploy and test a wide array of marketing materials aimed at adult smokers looking for ways to help them smoke less. These will include marketing at the point of sale, direct materials sent to self-identified adult smokers interested in VLN and online resources, such as our new product site at tryvln.com.”

    While 22nd Century owns or controls the intellectual property that makes VLN tobacco possible, the company has reiterated its willingness and expectation to license the technology to strategic partners.